Analyst Price Targets — IRD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 23, 2026 10:45 am | — | RBC Capital | $10.00 | $4.08 | TheFly | Opus Genetics initiated with an Outperform at RBC Capital |
| June 17, 2026 10:49 am | Matthew Caufield | H.C. Wainwright | $8.00 | $3.90 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Opus Genetics (IRD) |
| May 21, 2026 10:25 am | — | Leerink Partners | $10.00 | $4.44 | TheFly | Opus Genetics initiated with an Outperform at Leerink |
| March 11, 2026 1:17 pm | Albert Love | Craig-Hallum | $9.00 | $4.99 | StreetInsider | Craig-Hallum Reiterates Buy Rating on Opus Genetics (IRD): "continue to see significant upside opportunity" |
| January 20, 2026 10:44 am | Thomas Shrader | BTIG | $7.00 | $2.10 | TheFly | Opus Genetics initiated with a Buy at BTIG |
| November 25, 2025 10:16 am | — | Piper Sandler | $7.00 | $2.00 | TheFly | Opus Genetics initiated with an Overweight at Piper Sandler |
Latest News for IRD
RESEARCH TRIANGLE PARK, N.C., July 09, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company”, “Opus Genetics” or “Opus”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today provided updates on its ongoing OPGx-BEST1 Phase 1/2 clinical trial (BIRD-1) targeting BEST-1 associated IRDs.
Successful Type B RDEP Meeting confirms FDA alignment on pivotal Phase 3 study design FDA indicates Opus Genetics may submit a BLA based on 6-month efficacy data, with 12-month durability data provided during review Company expects to initiate Phase 3 dosing in 4Q 2026 RESEARCH TRIANGLE PARK, N.C., July 06, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a…
RESEARCH TRIANGLE PARK, N.C., June 26, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced the Company will be added as a member of the broad-market Russell 3000®, the Russell 2000® and the Russell…
Opus Genetics, Inc. (IRD) Discusses Early-Stage Gene Therapy Programs and Clinical Strategies for Inherited Retinal Diseases Transcript
Rapidly Advancing Five IRD Programs with Four Clinical Data Readouts Expected in 2027 RDH12, MERTK and RHO Programs Expected to Enter Clinical Testing over the Next 12 to 18 Months Cash Runway into 2029 Expected to Fund Multiple Clinical Inflection Points, Potential Product Approvals and Opportunities for Priority Review Vouchers IRD Prevalence Across Select Global Markets Provides a Significant Commercial…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IRD.
U.S. House Trading
No House trades found for IRD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.